M J Taylor1, B Godlewska1, J Near1, D Christmas2, J Potokar2, J Collier3, P Klenerman4, E Barnes4, P J Cowen1. 1. University Department of Psychiatry, Warneford Hospital, Oxford, UK. 2. Academic Unit of Psychiatry, School of Social and Community Medicine, University of Bristol, UK. 3. John Radcliffe Hospital, Oxford, UK. 4. NIHR Oxford Biomedical Research Centre, UK.
Abstract
BACKGROUND: The development of depressive symptomatology is a recognized complication of treatment with the cytokine interferon-α (IFN-α) and has been seen as supporting inflammatory theories of the pathophysiology of major depression. Major depression has been associated with changes in glutamatergic activity and recent formulations of IFN-induced depression have implicated neurotoxic influences that could also lead to changes in glutamate function. The present study used magnetic resonance spectroscopy (MRS) to measure glutamate and its major metabolite glutamine in patients with hepatitis C who received treatment with pegylated IFN-α and ribavirin. METHOD: MRS measurements of glutamate and glutamine were taken from a 25 × 20 × 20 mm voxel including the pregenual anterior cingulate cortex in 12 patients before and after 4-6 weeks of treatment with IFN. RESULTS: IFN treatment led to an increase in cortical levels of glutamine (p = 0.02) and a significant elevation in the ratio of glutamine to glutamate (p < 0.01). Furthermore, changes in glutamine level correlated significantly with ratings of depression and anxiety at the time of the second scan. CONCLUSIONS: We conclude that treatment with IFN-α is associated with MRS-visible changes in glutamatergic metabolism. However, the changes seen differ from those reported in major depression, which suggests that the pathophysiology of IFN-induced depression may be distinct from that of major depression more generally.
BACKGROUND: The development of depressive symptomatology is a recognized complication of treatment with the cytokine interferon-α (IFN-α) and has been seen as supporting inflammatory theories of the pathophysiology of major depression. Major depression has been associated with changes in glutamatergic activity and recent formulations of IFN-induced depression have implicated neurotoxic influences that could also lead to changes in glutamate function. The present study used magnetic resonance spectroscopy (MRS) to measure glutamate and its major metabolite glutamine in patients with hepatitis C who received treatment with pegylated IFN-α and ribavirin. METHOD: MRS measurements of glutamate and glutamine were taken from a 25 × 20 × 20 mm voxel including the pregenual anterior cingulate cortex in 12 patients before and after 4-6 weeks of treatment with IFN. RESULTS: IFN treatment led to an increase in cortical levels of glutamine (p = 0.02) and a significant elevation in the ratio of glutamine to glutamate (p < 0.01). Furthermore, changes in glutamine level correlated significantly with ratings of depression and anxiety at the time of the second scan. CONCLUSIONS: We conclude that treatment with IFN-α is associated with MRS-visible changes in glutamatergic metabolism. However, the changes seen differ from those reported in major depression, which suggests that the pathophysiology of IFN-induced depression may be distinct from that of major depression more generally.
Authors: Rejane G Tavares; Carla I Tasca; Candice E S Santos; Letícia B Alves; Lisiane O Porciúncula; Tatiana Emanuelli; Diogo O Souza Journal: Neurochem Int Date: 2002-06 Impact factor: 3.921
Authors: Peter Derek Christian Leutscher; Martin Lagging; Mads Rauning Buhl; Court Pedersen; Gunnar Norkrans; Nina Langeland; Kristine Mørch; Martti Färkkilä; Simon Hjerrild; Kristoffer Hellstrand; Per Bech Journal: Hepatology Date: 2010-08 Impact factor: 17.425
Authors: Stephen M Strakowski; Caleb M Adler; Jorge Almeida; Lori L Altshuler; Hilary P Blumberg; Kiki D Chang; Melissa P DelBello; Sophia Frangou; Andrew McIntosh; Mary L Phillips; Jessika E Sussman; Jennifer D Townsend Journal: Bipolar Disord Date: 2012-06 Impact factor: 6.744
Authors: D Häussinger; J Laubenberger; S vom Dahl; T Ernst; S Bayer; M Langer; W Gerok; J Hennig Journal: Gastroenterology Date: 1994-11 Impact factor: 22.682
Authors: Ebrahim Haroon; Bobbi J Woolwine; Xiangchuan Chen; Thaddeus W Pace; Samir Parekh; James R Spivey; Xiaoping P Hu; Andrew H Miller Journal: Neuropsychopharmacology Date: 2014-01-31 Impact factor: 7.853
Authors: David R Goldsmith; Ebrahim Haroon; Bobbi J Woolwine; Moon Y Jung; Evanthia C Wommack; Philip D Harvey; Michael T Treadway; Jennifer C Felger; Andrew H Miller Journal: Brain Behav Immun Date: 2016-04-01 Impact factor: 7.217
Authors: Jamie Near; Richard Edden; C John Evans; Raphaël Paquin; Ashley Harris; Peter Jezzard Journal: Magn Reson Med Date: 2014-01-16 Impact factor: 4.668
Authors: Ann L Sharpley; Charlotte M Cooper; Clare Williams; Beata R Godlewska; Philip J Cowen Journal: Psychopharmacology (Berl) Date: 2016-08-09 Impact factor: 4.530